Home › Atopic Dermatitis (Eczema) › Illinois › Chicago
Atopic Dermatitis (Eczema) clinical trials in Chicago, IL
5 studies for Atopic Dermatitis (Eczema) are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
RecruitingPhase 3
- Arcutis Site 320, Chicago
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
RecruitingPhase 2
- Enveda Investigative Site, Chicago
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RecruitingPhase 1
- Northwestern University Feinberg School of Medicine: Department of Dermatology, Chicago
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RecruitingPhase 4
- Lurie Children's Hospital/Northwestern University, Chicago
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
RecruitingObservational study
- Galderma Investigational Site 7058, Chicago
Atopic Dermatitis (Eczema) trials in other cities
- Los Angeles, CA12 studies
- New York City, NY12 studies
- Miami, FL11 studies
- Birmingham, AL10 studies
- Washington, DC10 studies
- San Antonio, TX9 studies
- Huntington Beach, CA9 studies
- San Diego, CA9 studies
- Dallas, TX8 studies
- Little Rock, AR7 studies
- Troy, MI7 studies
- Indianapolis, IN7 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.